The Economic Impact of Once-Daily versus Conventional Administration of Gentamicin and Tobramycin
- 1 November 1996
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 10 (5) , 494-503
- https://doi.org/10.2165/00019053-199610050-00007
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Aminoglycoside Dosage RegimensClinical Pharmacokinetics, 1993
- Once versus thrice daily gentamicin in patients with serious infectionsThe Lancet, 1993
- A Critical Reevaluation of the "Therapeutic Range" of AminoglycosidesClinical Infectious Diseases, 1992
- Once Daily Aminoglycoside Dosing: Maintained Efficacy with Reduced Nephrotoxicity?Renal Failure, 1992
- A prospective randomized study comparing once- versos twice-daily amikadn dosing in critically ill adult and paediatric patientsJournal of Antimicrobial Chemotherapy, 1991
- Once-daily aminoglycoside therapyAntimicrobial Agents and Chemotherapy, 1991
- Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided dosesJournal of Antimicrobial Chemotherapy, 1991
- Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacinJournal of Antimicrobial Chemotherapy, 1991
- Once-daily dosing regimen for aminoglycoside plus β-Lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxoneThe American Journal of Medicine, 1990
- Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990